Radiation therapy and sorafenib: Clinical data and rationale for the combination in metastatic renal cell carcinoma

Mohit Kasibhatla, Peter Steinberg, Jeffrey Meyer, Marc S. Ernstoff, Daniel J. George

Research output: Contribution to journalArticle

Abstract

Sorafenib, an inhibitor of multiple tyrosine kinases including vascular endothelial growth factor receptor and Raf/mitogen-activated protein kinase, increases progression-free survival in metastatic renal cell carcinoma (RCC) compared with placebo. The efficacy and toxicity of combined sorafenib and radiation therapy (RT) in the treatment of RCC are unknown. This is a retrospective report of 3 consecutive patients with metastatic or locally recurrent RCC treated with palliative RT while undergoing sorafenib therapy. All 3 patients experienced disease progression on sorafenib and remained on the drug without dose reduction during the RT plus sorafenib regimen. They were followed for toxicity and response by clinical history, physical examination, and contrast-enhanced computed tomography scans. Soon after completion of palliative RT, all 3 patients experienced complete pain relief without the need for narcotic pain medication. Posttreatment imaging revealed partial response with > 50% regression of tumor in all patients. None reported significant acute or late side effects at follow-up of 3, 6, and 8 months after RT and sorafenib. In the 3 patients with recurrent or metastatic RCC in this report, the combination of RT and sorafenib was well tolerated and resulted in excellent clinical and radiologic responses. This combination is promising and requires further study.

Original languageEnglish (US)
Pages (from-to)291-294
Number of pages4
JournalClinical Genitourinary Cancer
Volume5
Issue number4
DOIs
StatePublished - Jan 1 2007
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Radiotherapy
Palliative Care
Pain
Vascular Endothelial Growth Factor Receptor
Narcotics
sorafenib
Mitogen-Activated Protein Kinases
Protein-Tyrosine Kinases
Disease-Free Survival
Physical Examination
Disease Progression
Tomography
Placebos
Therapeutics
Pharmaceutical Preparations
Neoplasms

Keywords

  • Palliative therapy
  • Progressive disease
  • Tyrosine kinase inhibitors
  • Vascular endothelial growth factor receptor

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Radiation therapy and sorafenib : Clinical data and rationale for the combination in metastatic renal cell carcinoma. / Kasibhatla, Mohit; Steinberg, Peter; Meyer, Jeffrey; Ernstoff, Marc S.; George, Daniel J.

In: Clinical Genitourinary Cancer, Vol. 5, No. 4, 01.01.2007, p. 291-294.

Research output: Contribution to journalArticle

Kasibhatla, Mohit ; Steinberg, Peter ; Meyer, Jeffrey ; Ernstoff, Marc S. ; George, Daniel J. / Radiation therapy and sorafenib : Clinical data and rationale for the combination in metastatic renal cell carcinoma. In: Clinical Genitourinary Cancer. 2007 ; Vol. 5, No. 4. pp. 291-294.
@article{afbc56b47b5047ea806b4eac4446a08a,
title = "Radiation therapy and sorafenib: Clinical data and rationale for the combination in metastatic renal cell carcinoma",
abstract = "Sorafenib, an inhibitor of multiple tyrosine kinases including vascular endothelial growth factor receptor and Raf/mitogen-activated protein kinase, increases progression-free survival in metastatic renal cell carcinoma (RCC) compared with placebo. The efficacy and toxicity of combined sorafenib and radiation therapy (RT) in the treatment of RCC are unknown. This is a retrospective report of 3 consecutive patients with metastatic or locally recurrent RCC treated with palliative RT while undergoing sorafenib therapy. All 3 patients experienced disease progression on sorafenib and remained on the drug without dose reduction during the RT plus sorafenib regimen. They were followed for toxicity and response by clinical history, physical examination, and contrast-enhanced computed tomography scans. Soon after completion of palliative RT, all 3 patients experienced complete pain relief without the need for narcotic pain medication. Posttreatment imaging revealed partial response with > 50{\%} regression of tumor in all patients. None reported significant acute or late side effects at follow-up of 3, 6, and 8 months after RT and sorafenib. In the 3 patients with recurrent or metastatic RCC in this report, the combination of RT and sorafenib was well tolerated and resulted in excellent clinical and radiologic responses. This combination is promising and requires further study.",
keywords = "Palliative therapy, Progressive disease, Tyrosine kinase inhibitors, Vascular endothelial growth factor receptor",
author = "Mohit Kasibhatla and Peter Steinberg and Jeffrey Meyer and Ernstoff, {Marc S.} and George, {Daniel J.}",
year = "2007",
month = "1",
day = "1",
doi = "10.3816/CGC.2007.n.007",
language = "English (US)",
volume = "5",
pages = "291--294",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Radiation therapy and sorafenib

T2 - Clinical data and rationale for the combination in metastatic renal cell carcinoma

AU - Kasibhatla, Mohit

AU - Steinberg, Peter

AU - Meyer, Jeffrey

AU - Ernstoff, Marc S.

AU - George, Daniel J.

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Sorafenib, an inhibitor of multiple tyrosine kinases including vascular endothelial growth factor receptor and Raf/mitogen-activated protein kinase, increases progression-free survival in metastatic renal cell carcinoma (RCC) compared with placebo. The efficacy and toxicity of combined sorafenib and radiation therapy (RT) in the treatment of RCC are unknown. This is a retrospective report of 3 consecutive patients with metastatic or locally recurrent RCC treated with palliative RT while undergoing sorafenib therapy. All 3 patients experienced disease progression on sorafenib and remained on the drug without dose reduction during the RT plus sorafenib regimen. They were followed for toxicity and response by clinical history, physical examination, and contrast-enhanced computed tomography scans. Soon after completion of palliative RT, all 3 patients experienced complete pain relief without the need for narcotic pain medication. Posttreatment imaging revealed partial response with > 50% regression of tumor in all patients. None reported significant acute or late side effects at follow-up of 3, 6, and 8 months after RT and sorafenib. In the 3 patients with recurrent or metastatic RCC in this report, the combination of RT and sorafenib was well tolerated and resulted in excellent clinical and radiologic responses. This combination is promising and requires further study.

AB - Sorafenib, an inhibitor of multiple tyrosine kinases including vascular endothelial growth factor receptor and Raf/mitogen-activated protein kinase, increases progression-free survival in metastatic renal cell carcinoma (RCC) compared with placebo. The efficacy and toxicity of combined sorafenib and radiation therapy (RT) in the treatment of RCC are unknown. This is a retrospective report of 3 consecutive patients with metastatic or locally recurrent RCC treated with palliative RT while undergoing sorafenib therapy. All 3 patients experienced disease progression on sorafenib and remained on the drug without dose reduction during the RT plus sorafenib regimen. They were followed for toxicity and response by clinical history, physical examination, and contrast-enhanced computed tomography scans. Soon after completion of palliative RT, all 3 patients experienced complete pain relief without the need for narcotic pain medication. Posttreatment imaging revealed partial response with > 50% regression of tumor in all patients. None reported significant acute or late side effects at follow-up of 3, 6, and 8 months after RT and sorafenib. In the 3 patients with recurrent or metastatic RCC in this report, the combination of RT and sorafenib was well tolerated and resulted in excellent clinical and radiologic responses. This combination is promising and requires further study.

KW - Palliative therapy

KW - Progressive disease

KW - Tyrosine kinase inhibitors

KW - Vascular endothelial growth factor receptor

UR - http://www.scopus.com/inward/record.url?scp=34249878526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249878526&partnerID=8YFLogxK

U2 - 10.3816/CGC.2007.n.007

DO - 10.3816/CGC.2007.n.007

M3 - Article

C2 - 17553211

AN - SCOPUS:34249878526

VL - 5

SP - 291

EP - 294

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 4

ER -